Paula Nichaelle Aquino, APRN
Nurse Practitioner · Waipahu, HINPI 1831841006
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 159 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in HI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 159 payments — averaging $30.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$603
- Boston Scientific$572
- Bayer$545
- Lilly USA, LLC$506
- Abbott$428
- Amgen$371
- plus $2K from 18 others
What the payments were for
- Food & beverage$4,78998%
- Education$1232%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $603 |
| Boston Scientific | 9 | $572 |
| Bayer | 21 | $545 |
| Lilly USA, LLC | 17 | $506 |
| Abbott | 10 | $428 |
| Amgen(2 entities) | 14 | $371 |
| Corcept Therapeutics | 6 | $349 |
| AstraZeneca | 8 | $340 |
| Dexcom, Inc. | 10 | $317 |
| AbbVie | 10 | $239 |
| Boehringer Ingelheim | 6 | $119 |
| Insulet Corporation | 5 | $111 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $85 |
| Merck | 3 | $67 |
| Neurelis, Inc. | 2 | $45 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| GSK | 2 | $30 |
| Lundbeck LLC | 1 | $27 |
| Mannkind Corporation | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Medtronic | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$230
- WaveWriter Alpha Prime 16$164
- GENERAL PAIN MANAGEMENT$146
- DEXCOM G7 GSS (161)$135
- DEXCOM STELO GLUCOSE BIOSENSOR$135
- Kerendia$125
- AIRSUPRA$118
- Ozempic$116
- FREESTYLE LIBRE 3$116
- MOUNJARO$114
How this compares
$4,911 in reported general payments places this provider in the 90th percentile of 215 nurse practitioner providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 48 | $62,066 |
| JardianceEmpagliflozin | 30 | $40,616 |
| OzempicSemaglutide | 13 | $19,425 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $17,973 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 15 | $15,806 |
| TrulicityDulaglutide | 11 | $12,013 |
| Rosuvastatin Calcium | 138 | $4,123 |
| Atorvastatin Calcium | 135 | $2,432 |
| Amlodipine Besylate | 161 | $1,665 |
| Losartan Potassium | 122 | $1,510 |
| Colchicine | 21 | $1,427 |
| Ezetimibe | 39 | $1,403 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,314 |
| Omeprazole | 39 | $1,270 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 28 | $863 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $340 | $62,06648 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $119 | $56,42245 claims |
| Novo NordiskOzempic | $603 | $19,42513 claims |
| GSKTrelegy Ellipta | $30 | $17,97320 claims |
| Lilly USA, LLCTrulicity | $506 | $12,01311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 215 nurse practitioner providers in Hawaii.
Other nurse practitioner in Waipahu
- Ryan ArgyrosWaipahu$8K
- Hannah BernadskyWaipahu$4K
- Kimi PrenticeEwa Beach$65K
- Ashley SpringerHonolulu$43K
- Sung JungHonolulu$29K
- Judy KoHonolulu$17K
- Joanna AgenaAiea$16K
- Rosemarie ForondaWailuku$15K
- Bryce MontalboHonolulu$15K
- Anitalei AlexioAiea$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.